Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $763.7 million.

  • Ultragenyx Pharmaceutical's Other Non-Current Liabilities fell 794.89% to $763.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $763.7 million, marking a year-over-year decrease of 794.89%. This contributed to the annual value of $819.8 million for FY2024, which is 492.87% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Other Non-Current Liabilities of $763.7 million as of Q3 2025, which was down 794.89% from $782.7 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Other Non-Current Liabilities' 5-year high stood at $886.5 million during Q1 2023, with a 5-year trough of $340.2 million in Q1 2021.
  • Its 5-year average for Other Non-Current Liabilities is $685.4 million, with a median of $819.8 million in 2024.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Other Non-Current Liabilities surged by 14926.82% in 2023 and then plummeted by 794.89% in 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Non-Current Liabilities (Quarter) stood at $351.8 million in 2021, then surged by 148.86% to $875.4 million in 2022, then decreased by 1.5% to $862.3 million in 2023, then decreased by 4.93% to $819.8 million in 2024, then fell by 6.84% to $763.7 million in 2025.
  • Its Other Non-Current Liabilities stands at $763.7 million for Q3 2025, versus $782.7 million for Q2 2025 and $794.0 million for Q1 2025.